Business
Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease
- Top-Line Readout of Clinical Study Results Anticipated by the End of 2021 - Initiating Expanded Enrollment to New Participants in Open-Label Extension Study
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"- Top-Line Readout of Clinical Study Results Anticipated by the End of 2021\n - Initiating Expanded Enrollment to New Participants in Open-Label Extension Study KINECT-HD2\n\n\nSAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), in collaboration with the Huntington Study Group, today announced the completion of patient enrollment for its Phase 3 (KINECT-HD) clinical study evaluating the efficacy, safety and tolerability of valbenazine, a selective, orally active vesicular monoamine transporter 2 (VMAT2) inhibitor being investigated as a once-daily treatment in adults with chorea in Huntington disease. A top-line data readout of the clinical study results is anticipated by the end of 2021.\n\n \n \n \n \n \n \n\n \n\"This milestone reflects the progress that we have made in advancing valbenazine as a potential treatment for people living with chorea in Huntington disease and we look forward to sharing top-line results later this year,\" said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. \"I'd like to thank our partners at the Huntington Study Group, the Clinical Trials Coordination Center at the University of Rochester, New York, the KINECT-HD investigative staff, and especially the patients and families for their commitment and perseverance in completing enrollment in the face of all the challenges posed by the pandemic.\"\nParticipants who have completed KINECT-HD can enroll in KINECT-HD2, an open-label extension study to evaluate the long-term safety and tolerability of valbenazine for the treatment of chorea in Huntington disease. The KINECT-HD2 study is now also open to new patients who have not participated in the KINECT-HD study.\nHuntington disease impacts an estimated 30,000 adults in the United States. Chorea, an involuntary movement disorder, in which people develop abnormal, abrupt or irregular movements, is one of the most common symptoms, affecting roughly 90% of those diagnosed. Current treatments available for chorea are associated with increased risk of depression and suicidality.\n\"We're pleased to be part of these clinical studies and to see valbenazine move forward in its development as a potential therapy for people living with chorea in Huntington disease,\" said Andrew Feigin, M.D., Chair of the Huntington Study Group. \"We are grateful for our par...